Gene edit­ing star CRISPR Ther­a­peu­tics files for $90M IPO

In one of the most high­ly an­tic­i­pat­ed biotech IPOs of the year, CRISPR Ther­a­peu­tics has filed its S-1 out­lin­ing its plans to raise $90 mil­lion from an ini­tial pub­lic of­fer­ing.

CRISPR Ther­a­peu­tics is one of a hand­ful of the most promi­nent gene edit­ing com­pa­nies in the world, found­ed by Em­manuelle Char­p­en­tier, who’s cred­it­ed as one of the pi­o­neer­ing sci­en­tists be­hind CRISPR/Cas9 tech, which promis­es to open up a new chap­ter in drug de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER